Hoya’s Reports Strong IOL Sales in Fiscal 2017 Fourth Quarter

May 12, 2017: By Jon Swedien

Hoya logoHoya’s intraocular lens (IOL) sales were strong during its fiscal 2017 fourth quarter—Jan. 1 to March 31, 2017, according to the Japanese company.

The firm announced May 11 that its IOL sales for cataracts continued to perform well in Japan, after being introduced in the previous fiscal year. Outside of Japan, IOL sales grew, outpacing performance for the same period in the prior fiscal year “by a significant margin,” Hoya said.

Hoya’s Life Care business segment, which includes eyeglass lenses, contact lenses, and intraocular lenses (IOLs), plus other products, saw an increase in revenues of 3.5 percent, with sales totaling 83,752 million yen (US $739 million, as of May 12, 2017) in the quarter.

Hoya reported that its overall revenues increased 3.8 percent to 126,304 million yen (US $1.12 billion) in the company’s 2017 fiscal fourth quarter.

Revenues for the fiscal year ended March 31, 2017, totaled 478,927 million yen (US $4.23 billion), down 5.3 percent year over year.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023